vTv Therapeutics (VTVT) is a biopharma company with a market cap of $156 million, focusing on Alzheimer’s, diabetes, and inflammatory disorders. The stock has surged 182% in the past year, hitting a two-year high. Wall Street analysts are divided, with some bullish and others cautious due to uncertain fundamentals.

The company’s flagship drug candidate is azeliragon TTP488 for Alzheimer’s in Phase 3 trials, with other candidates for diabetes, cancers, psoriasis, and COPD. Technical signals indicate strong momentum and a recent 35.86% gain since December 8th. VTVT traded at a 2-year high of $41.49 on December 31st.

VTVT has a Weighted Alpha of +225.52, a 100% “Buy” opinion from Barchart, and a Trend Seeker “Buy” signal. The stock gained 182.36% in the past year, with a 50-day moving average of $30.06. It recently traded at $41.35 and made 14 new highs in the last month.

With a market cap of $156 million, VTVT is a speculative play heavily reliant on unproven pipeline assets. Analysts have price targets ranging from $35 to $47, with varying opinions from Strong Buy to Sell. Morningstar believes the stock is 22% undervalued.

This stock is a technical play with low short interest. Future revenue and earnings are uncertain, depending on drugs in trial stages. Despite the recent run-up, Morningstar believes there is still upside potential.

Read more at Yahoo Finance: An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here?